Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The effect of arteriovenous fistulaon hard endpoints should be observed prospectively in both CKD and non-CKD patients.

Zhao Y, Yang L, Mai H, Fu P.

Am J Hypertens. 2019 Jun 13. pii: hpz097. doi: 10.1093/ajh/hpz097. [Epub ahead of print] No abstract available.

PMID:
31219147
2.

Chronic kidney disease accelerates endothelial barrier dysfunction in a mouse model of an arteriovenous fistula.

Liang A, Wang Y, Han G, Truong L, Cheng J.

Am J Physiol Renal Physiol. 2013 Jun 15;304(12):F1413-20. doi: 10.1152/ajprenal.00585.2012. Epub 2013 Apr 10.

3.

CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas.

Kokubo T, Ishikawa N, Uchida H, Chasnoff SE, Xie X, Mathew S, Hruska KA, Choi ET.

J Am Soc Nephrol. 2009 Jun;20(6):1236-45. doi: 10.1681/ASN.2007121312. Epub 2009 May 7.

4.

Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease.

Chien CT, Fan SC, Lin SC, Kuo CC, Yang CH, Yu TY, Lee SP, Cheng DY, Li PC.

Thromb Haemost. 2014 Nov;112(5):1051-64. doi: 10.1160/TH14-03-0258. Epub 2014 Jul 17.

PMID:
25030617
5.

Timing of arteriovenous fistula creation in patients With CKD: a decision analysis.

Shechter SM, Skandari MR, Zalunardo N.

Am J Kidney Dis. 2014 Jan;63(1):95-103. doi: 10.1053/j.ajkd.2013.06.021. Epub 2013 Aug 24.

PMID:
23978336
6.

A new model of an arteriovenous fistula in chronic kidney disease in the mouse: beneficial effects of upregulated heme oxygenase-1.

Kang L, Grande JP, Hillestad ML, Croatt AJ, Barry MA, Katusic ZS, Nath KA.

Am J Physiol Renal Physiol. 2016 Mar 15;310(6):F466-76. doi: 10.1152/ajprenal.00288.2015. Epub 2015 Dec 16.

7.

Nitric Oxide Resistance Reduces Arteriovenous Fistula Maturation in Chronic Kidney Disease in Rats.

Geenen IL, Kolk FF, Molin DG, Wagenaar A, Compeer MG, Tordoir JH, Schurink GW, De Mey JG, Post MJ.

PLoS One. 2016 Jan 4;11(1):e0146212. doi: 10.1371/journal.pone.0146212. eCollection 2016.

8.

Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease.

Godino C, Melillo F, Rubino F, Arrigoni L, Cappelletti A, Mazzone P, Mattiello P, Della Bella P, Colombo A, Salerno A, Cera M, Margonato A; INSIghT investigators.

Intern Emerg Med. 2019 May 9. doi: 10.1007/s11739-019-02100-9. [Epub ahead of print]

PMID:
31073827
9.

Association of contrast-induced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention.

Watabe H, Sato A, Hoshi T, Takeyasu N, Abe D, Akiyama D, Kakefuda Y, Nishina H, Noguchi Y, Aonuma K.

Int J Cardiol. 2014 Jun 1;174(1):57-63. doi: 10.1016/j.ijcard.2014.03.146. Epub 2014 Mar 28.

PMID:
24726211
10.

Chronic kidney disease increases cardiovascular unfavourable outcomes in outpatients with heart failure.

Galil AG, Pinheiro HS, Chaoubah A, Costa DM, Bastos MG.

BMC Nephrol. 2009 Oct 21;10:31. doi: 10.1186/1471-2369-10-31.

11.

Vascular access for elderly hemodialysis patients: what should we aim for?

Ferreira H, Coentrao L.

J Vasc Access. 2016 Mar;17 Suppl 1:S38-41. doi: 10.5301/jva.5000503. Epub 2016 Mar 6. Review.

PMID:
26951902
12.

Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.

Lin TH, Lai WT, Hsin HT, Li AH, Wang CL, Kuo CT, Hwang JJ, Chiang FT, Chang SC; ACS Full Spectrum Registry Investigators.

PLoS One. 2013 Aug 28;8(8):e71917. doi: 10.1371/journal.pone.0071917. eCollection 2013.

13.

Effectiveness of Integrated Care on Delaying Progression of stage 3-4 Chronic Kidney Disease in Rural Communities of Thailand (ESCORT study): a cluster randomized controlled trial.

Jiamjariyapon T, Ingsathit A, Pongpirul K, Vipattawat K, Kanchanakorn S, Saetie A, Kanistanon D, Wongprompitak P, Leesmidt V, Watcharasaksilp W, Wang W, Chandraker AK, Tungsanga K.

BMC Nephrol. 2017 Mar 2;18(1):83. doi: 10.1186/s12882-016-0414-4.

14.

Performance of the Cockcroft-Gault, MDRD and CKD-EPI Formulae in Non-Valvular Atrial Fibrillation: Which one Should be Used for Risk Stratification?

Barra S, Providência R, Faustino C, Paiva L, Fernandes A, Leitão Marques A.

J Atr Fibrillation. 2013 Oct 31;6(3):896. doi: 10.4022/jafib.896. eCollection 2013 Oct-Nov.

15.

Cardiovascular remodeling during arteriovenous fistula maturation in a rodent uremia model.

Langer S, Paulus N, Koeppel TA, Greiner A, Buhl A, Krombach GA, Jacobs MJ, Kennes L, Kokozidou M.

J Vasc Access. 2011 Jul-Sep;12(3):215-23. doi: 10.5301/JVA.2010.6066.

PMID:
21104672
16.

Separate and joint effects of diabetes mellitus and chronic kidney disease on the risk of acute coronary syndrome: a population-based cohort study.

Chang YT, Liu CC, Tsai LM, Li CY, Sung JM.

Medicine (Baltimore). 2014 Dec;93(28):e261. doi: 10.1097/MD.0000000000000261.

17.

Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest.

Weidner K, Behnes M, Schupp T, Rusnak J, Reiser L, Taton G, Reichelt T, Ellguth D, Engelke N, Bollow A, El-Battrawy I, Ansari U, Hoppner J, Nienaber CA, Mashayekhi K, Weiß C, Akin M, Borggrefe M, Akin I.

Clin Res Cardiol. 2019 Jun;108(6):669-682. doi: 10.1007/s00392-018-1396-y. Epub 2018 Dec 21.

PMID:
30578436
18.

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients.

Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F, Vanholder R, Brigant B, Pletinck A, Diouf M, Burtey S, Choukroun G, Massy ZA, Metzinger L; European Uremic Toxin Work Group-EUTox.

Sci Rep. 2019 Mar 14;9(1):4477. doi: 10.1038/s41598-019-41101-8.

19.

Serum Non-High-Density Lipoprotein Cholesterol and Risk of Cardiovascular Disease in Community Dwellers with Chronic Kidney Disease: the Hisayama Study.

Usui T, Nagata M, Hata J, Mukai N, Hirakawa Y, Yoshida D, Kishimoto H, Kitazono T, Kiyohara Y, Ninomiya T.

J Atheroscler Thromb. 2017 Jul 1;24(7):706-715. doi: 10.5551/jat.37044. Epub 2016 Nov 12.

20.

Metabolic syndrome attenuates effect of chronic kidney disease on prevalence of coronary disease in men referred for stress imaging study.

Kamalesh M, Campbell S, Chong CK, Gipson A, Patel N, Ng C, Eckert GJ, Meda M, Sawada S.

Clin Nephrol. 2009 Mar;71(3):255-62.

PMID:
19281735

Supplemental Content

Support Center